GlaxoSmithKline plans to unveil today the results of clinical trials on several drugs, including one to treat diabetes, one of more than a dozen drugs the company has under development. The company has been overhauling its research and development division, and the progress on 13 drugs in Phase III trials out of about 90 products GSK is developing could be a positive response to investors who have been clamoring for results.

Related Summaries